Bo Shen/iStock Editorial via Getty Images Incyte ( NASDAQ: INCY ) reported positive results from a Phase 3 study of its drug Zynyz in the treatment of non-small cell lung cancer, or NSCLC. The study tested Zynyz, also known as retifanlimab, in combination with platinum-based chemotherapy for the treatment of previously.
Health